Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-1.11Last Year’s EPS
-1.11Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: -14.28%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mix of significant advancements in Beam's clinical programs, particularly in sickle cell disease and liver genetic diseases, alongside notable challenges related to patient safety in ongoing trials. While the progress in clinical data and technology development is promising, the safety concerns related to conditioning agents are a critical issue.Company Guidance
In the Q3 2024 earnings call, Beam Therapeutics provided comprehensive updates on its clinical programs, highlighting significant progress and future expectations. The company reported that 35 patients have been enrolled in the BEACON trial for BEAM-101, with 8 patients already treated. The trial evaluates BEAM-101 for sickle cell disease, aiming for a best-in-class profile through efficient editing and induction of fetal hemoglobin (HbF) to over 60%, significantly reducing sickle hemoglobin (HbS) levels. Beam also shared promising preclinical data for its ESCAPE technology, which aims to eliminate the use of chemotherapy in stem cell transplants, potentially expanding the patient population up to fourfold. Additionally, Beam announced the completion of dosing in the first cohort of its BEAM-302 program for alpha-1 antitrypsin deficiency (AATD) and expects to report initial data in 2025. Financially, the company remains strong, supporting the continued development and potential commercialization of its pipeline.Advancements in Sickle Cell Disease Treatment
Beam Therapeutics reported initial clinical data from the BEACON trial for BEAM-101, showing a significant increase in fetal hemoglobin (HbF) and a reduction in sickle hemoglobin (HbS) in patients with sickle cell disease. Patients achieved greater than 60% HbF, reducing HbS to less than 40%, which is consistent with sickle cell trait profiles.
Progress in Liver Genetic Disease Program
Beam-302, aimed at treating alpha-1 antitrypsin deficiency (AATD), has dosed its first patient, with plans to report initial data in 2025. This program intends to address both lung and liver manifestations of the disease.
ESCAPE Technology Development
Beam has nominated development candidates for ESCAPE technology, aiming to eliminate chemotherapy in transplants. Early nonhuman primate studies show promising engraftment and HbF induction without chemotherapy.
Strong Financial Position
Beam Therapeutics reported a strong financial position, supporting ongoing and future clinical development programs.
BEAM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BEAM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $19.82 | $15.99 | -19.32% |
Feb 25, 2025 | $30.79 | $29.84 | -3.09% |
Nov 05, 2024 | $24.36 | $23.93 | -1.77% |
Aug 06, 2024 | $25.61 | $25.52 | -0.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Beam Therapeutics (BEAM) report earnings?
Beam Therapeutics (BEAM) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Beam Therapeutics (BEAM) earnings time?
Beam Therapeutics (BEAM) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BEAM EPS forecast?
BEAM EPS forecast for the fiscal quarter 2025 (Q2) is -1.11.